Viva Biotech Holdings provided unaudited consolidated earnings guidance for the year ended December 31, 2021. For the year, the company expects that the revenue for the Year will increase by no less than RMB 1,300 million or over 180% to approximately RMB 2,000 million as compared to that for the year ended December 31, 2020. The Group expects to record a net profit of no less than RMB 300 million for the Year as compared with a net loss of RMB 378.9 million for the year ended December 31, 2020.

The Group expects to record a net profit attributable to the equity shareholders of the Company of no less than RMB 280 million for the Year as compared with a net loss attributable to the equity shareholders of the Company of RMB 386.9 million for the year ended December 31, 2020.